Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Unknown 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioma 2Oligodendroglioma 1Glioblastoma 1Astrocytoma 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × OKN 007 × Clear all
NCT05561374 2024-11-29

Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

Oblato, Inc.

Phase 1 Active not recruiting
16 enrolled
CNS

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma

NCT01672463 2023-03-29

OKN-007

Oblato, Inc.

Phase 1 Unknown
31 enrolled
CNS

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡